AEGiS-CATIE: ANTI-HIV AGENTS: AZT -- resistance may depend on dose Canadian AIDS Treatment Information Exchange
Click here to return to CATIE main menu
DonateNow

ANTI-HIV AGENTS: AZT -- resistance may depend on dose

TreatmentUpdate 71, Volume 8, No 7; October 1996
Sean Hosein


Study details

Although people living with HIV/AIDS using AZT are usually prescribed 500 or 600 mg/day, anecdoctal reports suggest that people may be taking 300 or 400 mg/day. This dose reduction may reduce side effects and the cost of the drug. Doctors in Mexico city conducted a small study to find out the effect of different doses of AZT on the development of drug-resistant virus. Doctors recruited 15 HIV-infected subjects who had between 200 and 500 CD4+ cells. Subjects were assigned to the following groups:

* AZT 500 mg/day

* AZT 300 mg/day

* no AZT (or any other anti-HIV drugs)

Blood samples were taken from the subjects for analysis before they entered the study and at regular intervals.

Results

During the course of the study, technicians isolated HIV from blood samples and exposed the virus to AZT in lab experiments. They found at the end of the study, HIV from subjects who used the high dose of AZT required huge quantities (750 times the normal amount) of the drug to suppress production of HIV in the test tube. Virus taken from subjects using AZT 300 mg/day needed less drug (93 times the normal level) to block its activity. Subjects not receiving AZT had HIV that required even less drug to suppress its production. The difference between the concentrations of AZT required to suppress the virus before and after entering the study was [statistically] significant.

Interpretation

Although researchers are not sure which dose of AZT is best, 300 mg/day in combination with other anti-HIV agents may be a reasonable dose to use. The study could have been a more useful piece of research had the doctors also measured changes in viral load.

REFERENCES:

1. Soto-Ramirez L, Renjifo B, Marlink R, et al . Dose-dependent HIV-1 Zidovudine resistance. Abstract I111.


961010
CATE7102


Always watch for outdated information. This article first appeard in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1996 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284  http://www.catie.ca


This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1996. AEGIS.